Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Refractory Head and Neck Cancer|Squamous Cell Carcinoma, Skin|Carcinoma of the Breast|Malignant Melanoma
Interventions: DRUG: HF10
Sponsor: Takara Bio Inc.